Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms

Journal of Infectious Diseases

Volumn 207, Issue 5, 2013, Pages 842-847

  Malmberg, Maja ^a   Ferreira, Pedro E ^a,c,h   Tarning, Joel ^d,e   Ursing, Johan ^a   Ngasala, Billy ^a,f   Björkman, Anders ^a   Mårtensson, Andreas ^a,b   Gil, José P ^a,c,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Division of Global Health   (Sweden)

^c UNIVERSITY OF ALGARVE   (Portugal)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^g BINGHAMTON UNIVERSITY   (United States)

^h NAGASAKI UNIVERSITY   (Japan)

Author keywords

antimalarials; artemether lumefantrine; drug resistance; in vivo; lumefantrine; malaria; pfmdr1; pharmacokinetics; Plasmodium falciparum

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COPY NUMBER VARIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; GENE; HAPLOTYPE; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; NONHUMAN; PARASITE LOAD; PLASMODIUM FALCIPARUM; PLASMODIUM FALCIPARUM MULTIDRUG RESISTANCE GENE 1; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REINFECTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE;

EID: 84873680525     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis747     Document Type: Article

References (21)

1. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemetherlumefantrine (Coartem). J Infect Dis 2005; 191:1014-7
2. Sisowath C, Ferreira PE, Bustamante LY, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 2007; 12:736-42
3. Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009; 199:750-7
4. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infection, Genetics and Evolution : Infect Genet Evol 2007; 7:562-9
5. Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007; 51:991-7
6. Martensson A, Ngasala B, Ursing J, et al. Influence of consecutive-day blood sampling on polymerase chain reaction-Adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis 2007; 195:597-601
7. Juliano JJ, Ariey F, Sem R, et al. Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis 2009; 200:624-8
8. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: Using the day-7 drug level? Trends Parasitol 2008; 24:159-63
9. Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: A randomized trial. Clin Infect Dis 2011; 52:873-82
10. Ngasala BE, Malmberg M, Carlsson AM, et al. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: An open label prospective study. Malar J 2011; 10:64
11. Blessborn D, Romsing S, Annerberg A, et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal 2007; 45:282-7
12. Hietala SF, Martensson A, Ngasala B, et al. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother 2010; 54:4780-8
13. Tarning J, McGready R, Lindegardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2009; 53:3837-46
14. Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemetherlumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570-7
15. Gadalla NB, Adam I, Elzaki SE, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother 2011; 55:5408-11
16. Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009; 53:5069-73
17. Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 2009; 58:201-9
18. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa: The beginning of the end? J Infect Dis 2005; 192:1303-4; author reply 4-5
19. Carlsson AM, Ngasala BE, Dahlstrom S, et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J 2011; 10:380
20. Djimde AA, Tekete M, Abdulla S, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2011; 55:3994-9
21. Domanski D, Percy AJ, Yang J, et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012; 12:1222-43